Availability and affordability of antimalarial and antibiotic medicines in Malawi

PLoS One. 2017 Apr 18;12(4):e0175399. doi: 10.1371/journal.pone.0175399. eCollection 2017.

Abstract

Background: Availability and affordability of medicines are key determinants of universal health coverage, yet achieving them presents a major challenge especially in low-income countries. We here present an analysis of availability and prices of antimalarial and antibiotic medicines in public, faith-based and private health facilities in Malawi. Medicines are provided free of charge in the public health care system of Malawi. In contrast, facilities of the Christian Health Association of Malawi (CHAM) usually charge their patients for medicines, as do private for-profit facilities.

Methods: As part of a study on medicine quality, samples of six antimalarial and six antibiotic medicines were collected in 31 health facilities in four districts of southern Malawi. These included 15 public facilities (i.e. health centres, district hospitals and central hospitals), eight CHAM and eight private facilities. Random selection was used in choosing the included health facilities. The availability of medicines was recorded, including the number of units which could be collected of each medicine, as well as the prices of medicines which were charged in CHAM and private facilities. These data were analyzed using the standard methodology developed by the World Health Organization (WHO) and Health Action International (HAI).

Results: Availability of the antimalarials artemether/lumefantrine and sulfadoxine/pyrimethamine, which are provided with financial support from international donors, was high in public and CHAM facilities (93% and 100%, respectively). However, availability of antibiotics was much lower (e.g. 40% availability of amoxicillin tablets/capsules in public health centres). Medicine prices were lower than reported from many other countries. The median price ratio (MPR) to a wholesale international procurement price was 2.8 in CHAM facilities and even lower in the private sector (MPR 2.3). Nevertheless, for 10 of the 12 investigated medicines the cost for one course of treatment exceeded the daily wage of a low-paid government worker in Malawi and therefore had to be considered as unaffordable for a major part of the population.

Conclusions: Continued efforts are required to improve the availability of essential medicines in Malawi. The free provision of medicines in the public health care system remains important in order to achieve universal health coverage, due to the low income in this country.

Publication types

  • Multicenter Study

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Antimalarials / therapeutic use*
  • Drug Costs / statistics & numerical data
  • Drugs, Essential / economics
  • Health Services Accessibility / economics*
  • Health Services Accessibility / statistics & numerical data*
  • Humans
  • Malawi
  • Private Sector / economics
  • Private Sector / statistics & numerical data
  • Public Sector / economics
  • Public Sector / statistics & numerical data
  • Quality of Health Care / economics
  • Quality of Health Care / statistics & numerical data

Substances

  • Anti-Bacterial Agents
  • Antimalarials
  • Drugs, Essential

Grants and funding

This study was financially supported by grant FA 83182402 of the Malawian-German Health Programme of the Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH and the German Federal Ministry for Economic Cooperation and Development (BMZ). The contribution by FK was supported by the Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Wellcome Trust (UK) (Grant No. 087547/Z/08/Z), the Carnegie Corporation of New York (Grant No. B 8606.R02) and Sida (Grant No. 54100029). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.